Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CX-5461 + CX-6258 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CX-5461 | CX5461|Pidnarulex|CX 5461 | CX-5461 is an RNA polymerase I (Pol I) inhibitor that inhibits rRNA synthesis, resulting in growth arrest and apoptosis in cancer cells (PMID: 26472108, PMID: 32719798). | ||
CX-6258 | CX6258|CX 6258 | PIM Inhibitor (Pan) 9 | CX-6258 is an inhibitor of PIM1, PIM2, PIM3 and Histone H3-associated protein serine/threonine kinase (HASPIN), which may potentially result in antitumor activity (PMID: 24900437) and may overcome tumor resistance to RAF/MEK-inhibitors (PMID: 31882401). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | prostate cancer | predicted - sensitive | CX-5461 + CX-6258 | Preclinical | Actionable | In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in decreased tumor burden in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174). | 27486174 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|